Vitura Health Ltd (ASX: VIT) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Vitura Health Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Vitura Health Ltd (ASX: VIT)
Latest News
Cannabis Shares
How did ASX cannabis shares perform in FY22?
Cannabis Shares
Remember when ASX cannabis shares were smoking hot? Where are they now?
Cannabis Shares
How have ASX cannabis shares been performing so far in 2022?
Cannabis Shares
This little-known ASX cannabis share has quietly gained 26% in a month to trade at all-time highs
Healthcare Shares
2 ASX healthcare shares bucking the trend to hit new highs on Friday
Share Gainers
These were the best-performing ASX cannabis shares in 2021
Share Gainers
Why is the Cronos (ASX:CAU) share price soaring 45% today?
Cannabis Shares
What's the outlook for ASX Cannabis shares in 2022?
Cannabis Shares
These were the top performing ASX cannabis shares in November
Share Market News
What's going wrong for ASX cannabis shares lately?
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
04 Sep 2023 | $0.0100 | 100.00% | Final | 28 Sep 2023 |
16 Sep 2022 | $0.0100 | 100.00% | Final | 11 Oct 2022 |
VIT ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Vitura Health Ltd
Vitura Health Ltd is focused on creating medicinal cannabis products and digital health solutions that connect and strengthen the ecosystem between patients, prescribers, pharmacists, and suppliers. The company has three business segments namely, the Medical segment, which involves the sale of medicinal cannabis products; the Clinics segment, which involves the operation of medicinal cannabis clinics; and the Consumer segment, which involves the sale of consumer (non-medical) products in Australia and previously in Asia. The company generates the majority of its revenue from the Medical segment. Geographically the company generates the majority of its revenue from Australia.
VIT Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
24 Apr 2024 | $0.11 | $-0.01 | -9.09% | 1,111,101 | $0.11 | $0.12 | $0.11 |
23 Apr 2024 | $0.11 | $-0.05 | -31.25% | 12,613,460 | $0.15 | $0.16 | $0.09 |
19 Apr 2024 | $0.16 | $-0.01 | -5.88% | 35,346 | $0.17 | $0.17 | $0.16 |
18 Apr 2024 | $0.17 | $0.00 | 0.00% | 79,348 | $0.17 | $0.19 | $0.17 |
17 Apr 2024 | $0.17 | $0.01 | 6.06% | 58,324 | $0.17 | $0.18 | $0.16 |
16 Apr 2024 | $0.17 | $0.01 | 6.25% | 91,283 | $0.17 | $0.19 | $0.17 |
15 Apr 2024 | $0.16 | $-0.02 | -11.43% | 264,484 | $0.18 | $0.18 | $0.16 |
12 Apr 2024 | $0.18 | $-0.02 | -10.53% | 49,723 | $0.18 | $0.18 | $0.17 |
11 Apr 2024 | $0.19 | $0.03 | 18.18% | 10,462 | $0.17 | $0.19 | $0.17 |
10 Apr 2024 | $0.17 | $0.00 | 0.00% | 269,540 | $0.17 | $0.19 | $0.17 |
09 Apr 2024 | $0.17 | $-0.01 | -5.88% | 36,955 | $0.17 | $0.17 | $0.17 |
08 Apr 2024 | $0.17 | $0.00 | 0.00% | 300,578 | $0.17 | $0.19 | $0.17 |
05 Apr 2024 | $0.17 | $0.01 | 6.06% | 115,447 | $0.17 | $0.17 | $0.17 |
04 Apr 2024 | $0.17 | $0.01 | 6.25% | 39,465 | $0.17 | $0.18 | $0.16 |
03 Apr 2024 | $0.16 | $-0.02 | -10.96% | 78,574 | $0.18 | $0.18 | $0.16 |
02 Apr 2024 | $0.18 | $-0.01 | -5.26% | 78,018 | $0.19 | $0.19 | $0.18 |
28 Mar 2024 | $0.19 | $0.01 | 5.56% | 58,354 | $0.18 | $0.19 | $0.18 |
27 Mar 2024 | $0.18 | $-0.01 | -5.41% | 174,281 | $0.19 | $0.19 | $0.17 |
26 Mar 2024 | $0.19 | $-0.02 | -10.00% | 258,469 | $0.20 | $0.20 | $0.18 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
15 Dec 2023 | Rodney Cocks | Issued | 1,241,808 | $335,288 |
Issue of securities.
|
30 Aug 2023 | Guy Headley | Expiry | 1,500,000 | $577,500 |
Options expired.
|
25 Aug 2023 | Guy Headley | Exercise | 1,500,000 | $405,000 |
Exercise of options.
|
25 Aug 2023 | Guy Headley | Buy | 1,500,000 | $405,000 |
Exercise of options.
|
21 Jul 2023 | Guy Headley | Expiry | 1,500,000 | $750,000 |
Options expired. As per announcement on 28-07-2023
|
19 May 2023 | Guy Headley | Sell | 18,750,000 | $6,000,000 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Rodney Damon Cocks | Chief Executive OfficerExecutive Director | Sep 2018 |
Mr Cocks is a Director of NewSouthern Capital Pty. Ltd., a private equity firm he co founded. Prior to joining Vitura, he was a member of the Senior Leadership Team at Linfox and was a Consultant at the Boston Consulting Group. Rodney served on the Counter Narcotics Team of the British Embassy in Afghanistan and with the United Nations in Afghanistan, Sri Lanka, Pakistan and Iraq and started his career as an Infantry Officer in the Australian Army. He is an admitted Lawyer to the Supreme Court of New South Wales, was a Fellow at Harvard University and named the 2005 Victorian Australian of the Year. In 2003, Rodney was awarded a Conspicuous Service Medal for his actions in the aftermath of the 2002 Bali bombings.
|
Mr Guy Rothwell Headley | Non-Executive Director | Dec 2021 |
Mr Headley has operated in the Australian Medicinal Cannabis space since 2016. He is a founding director of CDA Health Pty. Ltd. and has acted as a director of Burleigh Heads Cannabis Pty. Ltd. over the last seven years. He brings a wealth of knowledge regarding medicinal cannabis sales, distribution and compliance in the heavily regulated industry. Prior to working in the cannabis space, Guy spent more than 15 years in the construction and development sector overseeing the procurement and management of multimillion dollar projects across New Zealand, Australia and the United Kingdom. Guy is also a founding Director and Chairman of the Emerging Therapeutics Association of Australia.
|
Ms Marcia Ani Matekino Walker | Non-Executive Director | Dec 2021 |
Ms Walker brings experience in Medical Governance and formerly served on the board of the New Zealand Medical Association and as a member of the General Practitioner Council of the NZMA, a member of the Medicines Classifications Committee for the Ministry of Health NZ and acts as a Medical Examiner for the Royal New Zealand College of General Practitioners. Previously, she acted as a Medical Advisor to the Rua BioScience (formerly Hikurangi Hemp Company) and Treasurer for the New Zealand Resident Doctors Association.
|
Ms Jenelle Lee Frewen | Non-Executive Director | Sep 2022 |
Ms Frewen is an accomplished government strategist and adviser with more than two decades' experience spanning complex policy development and implementation in regulated industries. She has led several federal and state political campaigns, and advised a range of business clients on public affairs and regulatory policy. She has experience working at all three levels of government in Australia and in new areas of policy-making in technology, broadband and cyber safety. Jenelle also spent time in her early career working as a communications and media adviser in the private sector in Australia, and was a senior aide in municipal government in the United States. She is currently Principal Consultant with the Canberra-based advisory firm, Precision Public Affairs.
|
Mr Robert Iervasi | Non-Executive ChairmanNon-Executive Director | Feb 2024 |
Mr Iervasi is a Chair, Board Director, former Group CEO, CFO and General Counsel. Most recently he was the Group CEO of Asahi Beverages, which owns Carlton and United Breweries (CUB). Currently, Mr Iervasi serves as Chair at Luv a Duck and Charters Paper, and is a Non Executive Director at SPC Global. With a background in both corporate governance and consumer products, Mr Iervasi is experience as a CFO, General Counsel and CEO through the various executive and Board roles he has held, including Asahi Beverages, HS Fresh Foods Group, Allpress Expresso and Circular Plastics Australia.
|
Mr Thomas Godfrey Howitt | Chief Financial OfficerCompany Secretary | Aug 2020 |
-
|
Guy R. Headley | Chief Commercial Officer |
-
|
|
Thomas Godfrey Howitt | Chief Financial OfficerCompany Secretary |
-
|
|
Jessimine C.K. Jansen | Chief Operating Officer |
-
|
|
Ryan J. Tattle | Chief Revenue Officer |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Elizabeth Sarah Jansen <Stanford Investment Trust> | 118,957,765 | 21.30% |
Guy Rothwell Headley | 109,048,772 | 19.53% |
Cronos Global Holdings Inc. | 55,176,065 | 9.88% |
Matua Hasyo Charlie Jansen <Whanau Family Trust> | 47,738,638 | 8.55% |
HSBC Custody Nominees (Australia) Limited | 22,470,003 | 4.02% |
NewSouthern Investment Holdings 1 Pty. Ltd.<NewSouthern Investment Trust 1> | 21,000,000 | 3.76% |
NewSouthern Investment Holdings A Pty. Ltd. | 20,000,000 | 3.58% |
Stone Group Pty. Ltd. <Stone Children A/C> | 19,950,243 | 3.57% |
Ashanna Pty. Ltd. | 10,766,897 | 1.93% |
Hektares SG Holdings Pte. Ltd. | 6,665,216 | 1.19% |
UBS Nominees Pty. Ltd. | 5,974,530 | 1.07% |
Citicorp Nominees Pty. Limited | 4,958,589 | 0.89% |
Jessimine Jansen | 4,653,379 | 0.83% |
BNP Paribas Nominees Pty. Ltd. <IB AU Noms Retail Client DRP> | 4,266,870 | 0.76% |
Daniel Francis Birch <BES A/C> | 3,798,013 | 0.68% |
Ryan Tattle | 3,451,189 | 0.62% |
Arawhero Pty. Ltd. <Arawhero Super Fund A/C> | 2,975,604 | 0.53% |
Kanmed Investments Pty. Ltd. | 2,368,718 | 0.42% |
Marienburg Pty. Ltd. <Robinson Family A/C> | 1,779,160 | 0.32% |
BG & Dewar Pty. Ltd. | 1,373,500 | 0.25% |